Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-101 in Unresectable Hepatocellular Carcinoma Undergoing Y-90 Treatment
NCT06217094Phase 1Withdrawn
- Sponsor
- University of Florida
- Start
- Feb 2026
- Primary completion
- Jul 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pritumumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by University of Florida. Primary endpoint: Maximum Tolerated Dose at 2 months. Planned start Feb 2026; status: withdrawn.
02
Drugs
pritumumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06217094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217094.